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Community cancer care 
Primary care 
A B S T R A C T   
Purpose: Ireland’s Sláintecare health plan is placing an increased focus on primary care. A community oncology 
nursing programme was developed to train community nurses to deliver care in the community. While the initial 
pilot was proven to be clinically safe, no cost evaluation was carried out. This study aims to compare the costs of 
providing cancer support services in a day-ward versus in the community. 
Methods: 183 interventions (40 in day-ward and 143 in community) were timed and costed using healthcare 
professional salaries and the Human Capital method. 
Results: From the healthcare provider perspective, the day-ward was a significantly cheaper option by an average 
of €17.13 (95% CI €13.72 - €20.54, p < 0.001). From the societal perspective, the community option was cheaper 
by an average of €2.77 (95% CI -€3.02 – €8.55), although this was a non-significant finding. Sensitivity analyses 
indicate that the community service may be significantly cheaper from the societal perspective. 
Conclusions: Given the demand for cost-viable options for primary care services, this programme may represent a 
national option for cancer care in Ireland when viewed from the societal perspective.   
1. Introduction 
Cancer is one of the leading causes of morbidity and mortality across 
the world. An estimated 18.1 million new cancer diagnoses and 9.6 
million cancer deaths were reported by the Global Cancer Observatory 
in 2018 estimates(Bray et al., 2018). Cancer incidence is estimated to 
double by 2035(Bray et al., 2018) and with that both the costs and de-
mands of oncology services will similarly increase. As a result, health-
care providers such as the Health Service Executive (HSE) are seeking 
ways to either (i) directly reduce costs of cancer care or (ii) moving the 
provision of health care interventions from the secondary care setting to 
the primary and community care sectors (Rischin et al., 2000; Lowenthal 
et al., 1996; Sprandio, 2012), in order to reduce the pressures of an 
increasing cancer patient population and to reduce the cost associated 
with the provision of care, as well as to ease the difficulties placed on 
patients facing long journeys for their cancer care.(Hall and Lloyd, 
2008). 
Nurse-led interventions have become increasingly common as a way 
of enhancing the efficiency of care and improving resource-utilisation in 
the healthcare system. As an increasingly specialised profession, there 
are many opportunities for nurses to expand their roles within all sectors 
of healthcare provision. The literature reports that nurse practitioners 
are clinically effective (Newhouse et al., 2011) and cost-effective 
(Martin-Misener et al., 2015) in healthcare provision and role expan-
sion. Increased training for nurses has allowed for new enhanced ser-
vices to be provided for the patients’ benefit, with the healthcare 
provider and society also benefiting. Specialist cancer nursing in-
terventions have shown enhanced patient outcomes, experiences and 
improvement in cancer management, in terms of both clinical and cost 
outputs(Lewis et al., 2009; Aiken et al., 2014; Corner et al., 2013). 
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Patients value communication, nursing experience and personal edu-
cation while receiving care, which oncology nurses have been shown to 
demonstrate(Griffiths et al., 2012). 
The study was conducted in a catchment area of 22,572 km2. This 
leads to long journeys and poses problems for patients looking to access 
services located centrally in hospitals. Oncology patients deal with many 
challenges in receiving their care, such as disruption of work, social life, 
psychiatric disorders (Derogatis et al., 1983), depression, (Spiegel and 
Giese-Davis, 2003) anxiety (Stark and House, 2000) and a general 
decline in quality of life(Heidrich et al., 2006). There is also a demon-
strated strain on the family caregiver of those who receive oncology care 
(Stenberg et al., 2010). It should be incumbent to provide such people 
with every possible opportunity to improve both the quality and 
accessibility of their care. One such method is introducing oncology care 
to the community setting. Initiatives in USA (Lowenthal et al., 1996), 
Australia (Rischin et al., 2000) and in the United Kingdom (Hall and 
Lloyd, 2008) have shown success, in terms of patient preference, quality 
of care and cost, in moving oncology care services from secondary to a 
primary care setting. A recent study in USA has shown a decreased pa-
tient expense for those receiving oncology care in primary care rather 
than in secondary care setting(Gordan et al., 2018). 
In 2010, a community oncology nursing programme was developed 
in response to service pressures within acute Medical Oncology De-
partments in Ireland. The programme enables community nurses to 
provide shared nursing care to acute oncology patients at home and in 
primary care centres. The nurses first completed a specifically tailored 
Level 9 University-accredited education course. A pilot program of this 
initiative has been evaluated and was found to have had a positive 
impact on (i) patients, through a qualitatively demonstrated improve-
ment on quality of life and (ii) community and acute hospital-based 
oncology services, showing enhanced integration of patient care, both 
assessed qualitatively(O’Toole et al., 2013). The programme was 
introduced to HSE Community Healthcare Organisation (CHO) Area 2 
(Health Service Executive, 2014) and there has been an ever-increasing 
demand on the community oncology service since. Table 1 below in-
dicates the number of community oncology interventions in Galway in 
the last 3 years. The large increases in services provided between 
January and June 2019 can be attributed to an increase in the level of 
trained nurses, allowing for further roll out of safe primary care services. 
Costings were not undertaken in the initial evaluation as there was only 
a small volume of patients involved in the piloting of this programme. 
Hence, it was deemed necessary to complete a cost-comparison analysis 
of this new programme, before further roll-out was implemented 
nationally. 
Ireland is in the process of implementing a 10-year plan for health 
reform called Sláintecare. The aim is to establish a universal, single-tier 
health service as well as re-structuring the health system “towards in-
tegrated primary and community care that is consistent with the highest 
quality of patient safety in as short a time-frame as possible”(Burke 
et al., 2018). There is an aim to move health services into primary care 
where possible. The community oncology programme examined here 
aims to provide both a safe and viable method of delivering cancer 
services in the community instead of providing the same care within an 
oncology day-ward of an acute hospital. This was the first study of its 
kind to the best of the author’s knowledge. 
2. Methods 
This study utilised a micro-costing approach to calculate costs in the 
hospital and community settings, both from the healthcare provider’s 
perspective and the societal perspective in Ireland during the latter 
months of 2019. Micro-costing is a type of costing method involving the 
direct enumeration and costing out of every input consumed during an 
intervention(Weinstein et al., 1996). It has become the gold-standard of 
costing methods due to its precise nature. Studies comparing the cost 
estimates made by micro-costing studies versus gross costing studies, 
whereby average costs are identified per treatment group (Drummond 
et al., 2015), have shown that micro-costing methods produce superior 
results, especially in the context of this study that takes place in a hos-
pital and where the main driver of cost is labour-related costs(Clement 
et al., 2009; Tan et al., 2009; Wordsworth et al., 2005; Swindle et al., 
1999). 
2.1. Study sites 
2.1.1. Hospital 
The oncology day ward that was costed as part of this study is a 
University teaching hospital in the west of Ireland, with 521 beds 
providing a range of specialities. Patients are assessed and manages and 
treatment and interventions include chemotherapy, adjuvant therapies, 
5-Flurouracil (5-FU) pump disconnections, catheter insertion supportive 
care and dressings. 
2.1.2. Community 
The community service was costed in two counties in the west of 
Ireland (Galway and Mayo). For each county, a community nurse who 
has completed the community oncology education programme is 
responsible for a given area and population. Patients in this area are 
given care in either Primary Care centres located in the given area, or in 
the patient’s own home depending on certain circumstances. 
2.2. Intervention 
Several oncology interventions have been deemed suitable to be 
delivered in the community. Governance over the patient population 
and the interventions which can be delivered in primary care rests with 
the consultant and his/her cancer team in secondary care. The nurses 
carried out interventions such as 5-FU pump disconnections, PortaCath 
flushes, the care of Peripherally Inserted Central Catheter (PICC) lines 
and Hickmann lines, head-to-toe patient assessment and other auxiliary 
oncology services such as medication administration, medication man-
agement and blood sampling. These services were carried out under HSE 
best practice and values, in accordance with the community oncology 
nursing programme resource book (available on request). 
2.3. Process mapping 
In order to carry out an accurate micro-costing, process maps were 
created for all sites involved in the study during 2019. This involved 
consultation with process leaders in the sites, these being the nurse 
managers, followed by direct observation of the patient and nursing 
pathways by the lead author (COM). The finalised process maps can be 
seen in Figs. 1, 2 and 3 below. The process maps were designed at a top- 
level manner, aiding in outline each step in the respective processes. 
This was needed to identify resource utilisation across all sites, at the 
start of the micro costing study. 
Table 1 
Number of community oncology services in Galway.  





January 2017 – 
June 2017 
349 693 1042 
July 2017 -December 
2017 
369 657 1026 
January 2018 – 
June 2018 
330 715 1045 
July 2018 – 
December 2018 
388 762 1150 
January 2019 – 
June 2019 
435 1353 1788  
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Fig. 1. Oncology day ward process map.  
Fig. 2. Community care process map.  
Fig. 3. Community care process map continued.  
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2.4. Cost-comparison analysis 
A micro-costing approach was undertaken to accurately calculate 
costs. Both the healthcare provider and societal perspective were 
calculated, based upon available costs and measurements taken in 2019. 
Direct and indirect costs were calculated. Direct costs included health-
care professional time, expenses and consumable cost. Indirect costs 
included patient productivity time lost, travel costs and overheads. The 
currency used in all cases was Euro (€). 
To calculate time-related costs, active time spent by nurses on car-
rying out tasks related to the patient’s oncology care were recorded 
using a direct observation approach with a stopwatch. Patient-related 
time costs were calculated from total time spent waiting as well as 
travel time, using patient self-reported times. For nurses travelling to 
patients’ homes, nurse travel time was recorded using an observation 
sheet and stopwatch (Appendix 1). The HSE healthcare professional pay 
scale (as per 2019) was used to cost the times observed. The midpoint of 
the relative professions pay scales (Health Service Executive, 2018) was 
used and adjusted for according to guidelines for economic evaluations 
in Ireland, (Health Information and Quality Authority, 2019) including 
pension payments, insurance and overheads. The hourly consultation 
rate was calculated by dividing the midpoint salary by the number of 
weeks worked per year and the number of hours worked per week. The 
number of weeks worked per year is 48 and the hours per week are 39. 
Public health nurse rates were applied to the community observations, 
and staff nurse rates were applied to the in-hospital day ward observa-
tions. Patient time-related costs were calculated using the Human Cap-
ital Method.(Van Den Hout, 2010) The average national hourly income 
as of 2019 Q2 (€23.81) was used.(Central Statistics Office, 2019) This 
method has been used previously to detail production loss in cancer 
(Norum et al., 2007; Stanisic et al., 2010). No discounting was needed 
given that the data collection period was carried out over 3 months. 
Similar methods of time-related cost calculation have been used by the 
study team previously(O’Brien et al., 2018, 2019). 
The procedures that were costed were the head to toe patient 
assessment, 5-FU pump disconnection, PICC line dressing, PortaCath 
Flush, Hickman lines and some miscellaneous procedures. Nursing ex-
perts were consulted on the consumables used in each of these processes. 
The costs of consumables were determined by invoices issued from the 
finance department of the hospital involved in the programme in 2019. 
The resource utilisation and unit costs of consumable were used to 
calculate the total consumable cost for each process. This is outlined in 
Table 2. The cost of consumables used in the community are the same as 
those used in the hospital. 
Total cost of a procedure was calculated from the public healthcare 
payer’s perspective (HSE), by summing the total consumable cost and 
healthcare professional costs (procedure time, travel time, travel ex-
penses), and the societal perspective cost, which was calculated by 
summing the cost of patient time and expenses to the health payer’s cost. 
There was no clinical data recorded in this study. This is because the 
pilot study for the Community Oncology Nursing Programme demon-
strated no clinical difference in providing care in the two settings (19). 
During the evaluation period there were no adverse events reported 
among the patients who were treated at home by the PHNs. There were 
no emergency phone calls made by the PHNs to the mobile phone 
number that had been specifically available for consultations and en-
quires as well as emergencies. While there was no quantitative assess-
ment of a change in patient quality of life, a qualitative assessment found 
an emphasis on the improvement of quality of life for patients treated in 
the community. The training provided by this programme is crucial to 
the viability of this project. The majority of the community nurses car-
rying out the interventions in the community would have no formal 
education specialising in oncology care prior to completing this pro-
gramme. Without this programme, any cost study would need to detail 
clinical values for a cost-effectiveness study to be completed. Given that 
there was found to be no difference in clinical outcomes, comparing the 
costs incurred in both settings is enough to determine the viability of this 
intervention. 
The costs in both settings were analysed graphically and formally 
using Kolmogorov-Smirnov and Shapiro-Wilks. Parametric data were 
compared using an independent sample two-tailed t-test, with α level 
0.05 to test for significance. Levene’s test for variance equivalence was 
used, and equal variance was not assumed if a significant result was 
found. For the cost-comparison analysis, the cost of consumables was 
excluded to remove it as a confounder i.e. The consumables used for 
each procedure do not vary between hospital and community settings. A 
cost-comparison analysis for procedures carried out in both settings was 
completed, as there were some procedures only observed in the com-
munity setting. The cost of community interventions in the two counties 
was compared using an independent samples t-test. 
2.5. Sensitivity analysis 
Although most day ward procedures are carried out by staff nurses, a 
portion of procedures are carried out by clinical nurse specialists. The 
costs incurred using a clinical nurse specialist hourly rate at levels of 5%, 
10% and 15% involvement was calculated.(Health Service Executive, 
2018). 
Given that many cancer patients are too unwell to travel alone, a 
sensitivity analysis was undertaken to examine the impact of another 
person accompanying the patient on the social cost (without consum-
ables) of the intervention. The cost of this person was calculated using 
the same Human Capital Method as the patient cost. To examine the 
variable effects of a patient being accompanied, 20%, 40%, 60%, 80% 
and 100% of the sample in all settings were analysed as if another person 
had accompanied them. For interventions carried out in the patient’s 
home, no increase in cost was incurred, as there would be no need for an 
accompanying carer. The difference in cost between secondary and 
Table 2 
Consumables used per single procedure.  
Items Pump disconnection Port Flush PICC dressing Hickmann Dressing     
Single lumen Double lumen Triple lumen 
Heparinised Saline 10 units per ml 1 1 2 1 2 3 
Sterile posiflush syringe 1 2 4 3 4 6 
Syringe luer lock 1 2 4 3 4 6 
Sani Cloth 2 3 6 4 6 8 
Sterile Dressing Pack  1 1    
NeutraClear Needle Free Connector  1 2    
Filter Needle 1 1 2 1 2 3 
Gloves Surg Gammex  1 2 2 2 2 
Dressing Opsite IV 3000   2 2 2 2 
Gripper Needles  1     
Gauze square 2      
Opsite post op 6.5v5cm 1 1     
Chemotherapy gloves 2       
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primary care interventions in this group was analysed using indepen-
dent samples t-test. 
2.6. Ethical considerations 
Ethical approval was granted from the clinical research ethics com-
mittees of both the local hospital network and primary care network in 
the region (Saolta University Health Care Group C.A 2084). 
2.7. Guidelines 
This paper was reported in accordance with the International Society 
for Phramacoeconomics and Outcomes Research (ISPOR) Consolidated 
Health Economic Evaluation Reporting Standards (CHEERS) guidelines 
for reporting health economic evaluations(Husereau et al., 2013). 
2.8. Software 
Analysis was carried out using IBM SPSS Statistics Version 24 and 
Microsoft Excel 2016. Process maps were created using Microsoft Van 
Den Hout, 2010. 
3. Results 
Table 3 below details the cost of consumables as provided by the 
finance department used in each procedure identified in the process 
mapping exercise e.g. the costliest procedure was a Hickmann 2 dressing 
at €8.37. 
3.1. 3.1 Healthcare professionals’ cost 
The annual salary midpoint for staff nurses is €38,546, resulting in an 
adjusted salary of €53,868 and an hourly consultation rate of €28.76. 
The annual salary midpoint for public health nurses is €54,888, resulting 
in an adjusted salary of €76,110 and an hourly consultation rate of 
€40.66. 
3.2. Cost comparison analysis 
A total of 183 procedures were analysed over the study period (be-
tween April and August 2019), 40 from the hospital setting and 143 from 
the community. Ideally an equal number of interventions would have 
been assessed across both settings but this was not feasible due to the 
lesser number of interventions that occur in the hospital. The number of 
each type of intervention is shown in Table 4. 
As shown, some interventions were recorded only in the community 
setting. As such, an analysis of procedures recorded in both settings was 
deemed necessary. 
Descriptive statistics of observations in each setting are shown in 
Table 5. Given all recordings were normally distributed, the mean and 
standard deviation are shown. Given that for the purpose of this analysis 
waiting time and travel time can be grouped together, these are com-
bined in the variable additional time. 
The cost of procedures from the healthcare payer’s perspective was 
analysed. Equal variance was not assumed. The hospital setting was 
shown to be an average of €17.07 (95% CI €14.02 - €20.12, p < 0.001) 
less costly per procedure. When selecting only procedures done in each 
setting, equal variance again was not assumed and the hospital setting 
was an average of €17.13 (95% CI €13.72 - €20.54, p < 0.001) less costly 
per procedure. 
For the societal perspective, equal variance was assumed. The com-
munity setting was cheaper by an average of €2.77 (95% CI -€3.02 – 
€8.55) per procedure, although this was a non-significant result (p =
0.347). When selecting only procedures done in each setting, a similar 
result was found, with the community setting being cheaper by an 
average of €3.47 (95% CI -€2.84 - €9.75), again a non-significant dif-
ference (p = 0.278). 
3.3. Home care versus primary care 
The cost of providing the interventions in the primary care centre 
was significantly lower when compared to interventions in the patient’s 
own home, from both the healthcare payer’s and societal perspective. 
Equal variance was assumed in both comparisons. The primary care 
centre was an average of €15.36 (95% CI €10.83 - €19.89, p < 0.001) 
from the healthcare payer’s perspective and an average of €7.59 (95% CI 
€2.44 - €12.73, p = 0.004) from the societal perspective. 
Comparing the cost of only interventions carried out in the primary 
care centre versus those in the hospital, the hospital was found to be 
cheaper by an average of €5.69 (95% CI -€1.09 - €12.47) from the 
Table 3 
Consumables cost. The consumables used for each procedure 
do not vary between hospital and community settings. As 
such, it was excluded from the cost comparison analysis.  
Procedure Cost (€) 
5FU pump disconnection 3.32 
PICC line dressing 8.31 
PortaCath flush 7.11 
Hickmann 1 dressing 5.77 
Hickmann 2 dressing 8.37 
Hickmann 3 dressing 11.98  
Table 4 
Number of each intervention analysed.   
Hospital Community Total 
5-FU disconnection 18 65 83 
PICC line dressing 2 9 11 
PortaCath Flush 18 7 25 
Hickmann 1 0 0 0 
Hickmann 2 0 8 8 
Hickmann 3 0 9 9 
Multiple procedures 2 13 15 
Neulasta/Neupogen injections 0 26 26 
Other 0 5 5 
Missing 0 1 1 
Total observations 40 143 183  
Table 5 














45.03 (33.31) 10.35 (12.38) 
Nurse travel 
costs (€) 





























32.46 (19.47) 38.14 
(19.29) 
29.69 (15.38) 34.81 
(15.22)  
a Travel time + waiting time. 
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healthcare payer’s perspective, but this was not a significant difference 
(p = 0.098). From the societal perspective, the primary care centre was 
cheaper by an average of €11.15 (95% CI €8.49 - €13.89) (p < 0.001). 
Table 6 below details the location of interventions carried out in the 
two counties. Comparing the cost of interventions in the two counties, 
interventions carried out in Mayo was shown to be an average of €6.96 
(95% CI €1.88 - €12.02) cheaper from the health payer’s perspective and 
€5.34 (95% CI €0.34 – €10.36) cheaper from the societal perspective (p 
= 0.008 and p = 0.034 respectively). 
3.4. Sensitivity analysis 
The salary midpoint of a clinical nurse specialist was €54,462, 
resulting in an adjusted annual salary of €76,706 and an hourly 
consultation rate of €40.975, resulted in a 41% increase in staff costs in 
the hospital setting. The societal cost of clinical nurse specialists car-
rying out 5%, 10% and 15% of procedures resulted in the community 
care being cheaper by €2.92 (95% CI -€2.82 – €8.76, p = 0.331), €3.10 
(95% CI -€2.61 – €8.96, p = 0.317) and €3.22 (95% CI -2.42 – €9.08, p =
0.302) respectively. None of these findings were significant. 
The cost of accompanying supporters of patients examined at rates of 
20%, 40%, 60%, 80% and 100% of interventions is detailed in Table 7. 
Equal variance was not assumed for comparisons. 
At all rates above 40%, there was a significant difference in mean 
cost, ranging from €8.66 (95% CI €0.96 - €16.36, p = 0.03) at 40%, to 
€15.90 (95% CI €7.61 - €21.20, p < 0.01) at 100%. 
4. Discussion 
This study showed that there is a significant cost increase in 
providing this service in the community from the health payer’s 
perspective, with a mean difference of €17.07 p < 0.001). This was 
expected given the increased staff costs in travelling in the community. 
Nurse travel time was the primary driver in this cost increase, with 
average nurse travel time in all community interventions being 13.22 ( 
±10.39) minutes, equating to €9.09 (+/− €7.14) in salary cost. The 
travel costs incurred also played a role in the increase. The average 
procedure time was significantly longer in the community (p < 0.001), 
even when examining only similar procedures. This may be due to the 
additional public health role of the nurses delivering the oncology care, 
as described in the community oncology handbook (available on 
request). 
This study captured the societal perspective by calculating the loss of 
productivity via the human capital method as well as the health care 
payer perspective. Sanders et al. recommended for the sake of consis-
tency and comparability, analysts should report “reference cases” from 2 
perspectives— the health care sector perspective and the societal 
perspective(Sanders et al., 2016). This was also corroborated by an 
ISPOR Special Task Force report (Garrison et al., 2018). When using the 
societal perspective, this study found that there was no significant dif-
ference in the cost of delivering the oncology services between the two 
settings. A non-significant cost reduction of €2.77 (p = 0.278) when 
delivering interventions in the community was discovered. The primary 
reason for this change compared to the health payer’s perspective is the 
reduction in patient travel time. The patient travel time is reduced by an 
average of 35 min (95% CI 27.97 min–41.38 min). This finding may be 
as important as the cost-saving from the health payer’s perspective, 
given that a central aim of Sláintecare is an accessible and affordable 
healthcare system for all, with an increased focus on patient-centred 
care(Burke et al., 2018). 
The analysis of the different primary care settings showed the ex-
pected result that the primary care centre was a cheaper option for the 
health payer, being an average of €15.36 (, p < 0.001) than the patient’s 
home. The primary care centre was found to be an average of €5.69 
(95% CI -€1.09 - €12.47) more expensive than the hospital from the 
health payer’s perspective but not significantly (p = 0.098). This may be 
because the community nurses were recorded in some instances to be 
travelling back to the centre after dealing with a house call. From the 
societal perspective, the primary care centre was significantly cheaper 
than the hospital, by an average of €11.15 (95% CI €8.49 - €13.89, p <
0.001). It is important to note that as part of any oncology primary care 
package home visits will be a necessity. Given their condition, certain 
patients require a home visit. This finding does show that from a societal 
perspective, interventions given in a primary care centre close to a pa-
tient’s home represent a significant cost reduction, before even consid-
ering the improvement in access to services from the patient’s 
viewpoint. 
While all analyses indicated that providing the intervention in the 
community resulted in a significant cost increase for the health payer, 
the sensitivity analyses demonstrated that there is a possibility that 
providing this cancer care in the community represents a cheaper 
alternative from the society perspective. Frail oncology patients are 
often accompanied for travel and support reasons. This study found that 
in a scenario where a randomly selected 40% of the patients in both 
settings were accompanied by another person, a significant cost reduc-
tion of €8.66 (95% CI €0.96 - €16.36, p = 0.03) was observed. This trend 
continued the more patients that were accompanied. Unfortunately, the 
study did not record if someone had travelled with the patient or not. 
When viewing from the societal perspective, these are welcome 
findings for the development of oncology care in Ireland. Providing 
oncology support services in the community is in line with the aims of 
Sláintecare, and this study shows that this represents a viable economic 
option. By moving these services away from oncology day unit within 
busy acute hospitals, there would be benefits for all. The freed-up space 
in the oncology would allow for more of the treatments that can only be 
provided in the day unit, such as chemotherapy. In addition to the 
economic benefits, there may be a quality of life benefit for the oncology 
patient by providing these interventions in the community, due to a 
reduced risk of infection associated with travel to hospital(Plowman, 
2000). Patients have stated their preference for receiving oncology care 
in their own home(Rischin et al., 2000). The reasons include avoidance 
of travel and parking problems, reduction in hospital-associated anxiety, 
feeling of comfort in their own home and not burdening their carers and 
family. 
Given that these oncology support interventions can be provided in a 
cost-effective manner, there may be scope for expanding the duties of 
community nurses to include other oncology services. The UK has long 
Table 6 
Location of community interventions.   
Primary Care Centre Patient’s home Missing Total 
Galway 22 39 1 62 
Mayo 34 38 0 82 
Total 56 87 1 144  
Table 7 
Cost of patient accompaniment.  
% of patients being 
accompanied 
































15.90 (p = 0.006)  
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allowed for chemotherapy to be administered as part of primary care 
(Lennan et al., 2010). Even if only the less complex interventions were 
handled in the community, this would further reduce the demands on 
the day wards within our acute hospitals. There is also appetite amongst 
both patients and nurses for blood samples to be collected in the com-
munity to streamline the chemotherapy administration process. 
All interventions analysed were from two counties in the West of 
Ireland. One of the counties is particularly sparsely populated. This may 
skew the travel times of both patients and nurses, as many other counties 
in Ireland may have primary care centres and hospitals available at a 
shorter distance. The average distance to healthcare facilities can be up 
to seven times larger in rural areas than urban areas.(Central, 2016 
Table 8 below shows the population density of the counties in the study 
compared to other Irish counties. 
This study used time recordings across community and hospital 
settings to compare the cost of delivering oncology support services. A 
micro-costing methodology was used. Other studies in this area have 
shown some differing results, albeit with different methodologies and 
focuses. Rischin et al. used direct and indirect costs based on services 
received and found that the average chemotherapy treatment was $83 
more expensive to deliver in the community than in hospital(Rischin 
et al., 2000). Gordan et al. discovered a significant decrease in cost per 
patient per month when delivering care in community oncology clinics 
compared to hospital clinics, primarily driven by the increased cost of 
chemotherapy and provider visits in hospital-based clinics(Gordan et al., 
2018). No previous study of this kind has used the precise, micro-costing 
method of cost collection used in this study. 
4.1. Limitations 
The only costs estimated in this study were the costs incurred in the 
carrying out of the oncology interventions. The cost of training in the 
Community Oncology Nursing Programme is not included in this anal-
ysis. If this cost were included, it would favour the hospital setting. 
However, given that this is a lifelong qualification, it may be biased to 
include the cost of training when analysing the sample of interventions 
recorded. If it was included, the average cost per intervention carried 
out by a trained community nurses over the duration of her career would 
be negligible. 
Ideally, a larger number of interventions would have been analysed 
for more robust results. These would ideally have come from the hospital 
setting to get more equitable sample sizes to compare, and thus provide 
more precise comparisons. However, where possible these support ser-
vices were carried out in the community to free up needed space in the 
day unit, an imbalance in the proportion carried out in the community 
compared to the hospital was expected. 
The sensitivity analyses were needed due to a lack of information 
regarding the type of staff who carried out the intervention and if the 
patient was accompanied by another person. The sensitivity analysis 
attempting to assess the impact of patients being accompanied to the 
hospital by carers only assessed accompaniment to the hospital. While 
the journey to the community centre may be less arduous, it is possible 
that the patient could be accompanied by a carer in that circumstance. 
5. Conclusion 
This study has shown that providing oncology support services in the 
community in Ireland can be a viable economic option when viewed 
from the societal perspective. The community oncology nursing pro-
gramme has demonstrated safety in its provision of these interventions 
in the community, this shows that the services that these trained com-
munity nurses provide may be a cost-effective service. Given previous 
studies have shown the preference for community interventions and 
with Ireland’s increasing focus on building a health system emphasising 
primary care, this community oncology programme may provide an 
option in reducing the oncology demands in hospital. 
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